151 related articles for article (PubMed ID: 35763306)
21. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
[TBL] [Abstract][Full Text] [Related]
22. Enhancement and Comparison of (Ceftazidime-)Avibactam Plus Aztreonam Susceptibility Tests for Stenotrophomonas maltophilia in Clinical Diagnostics.
Vlaspolder GL; Hughes LA; Huis In 't Veld RAG; Kampinga GA; Bathoorn E
Curr Microbiol; 2023 Dec; 81(1):28. PubMed ID: 38051338
[TBL] [Abstract][Full Text] [Related]
23.
Chen T; Xu W; Yu K; Zeng W; Xu C; Cao J; Zhou T
Microb Drug Resist; 2021 Mar; 27(3):401-409. PubMed ID: 32721272
[No Abstract] [Full Text] [Related]
24. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
25. Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
Mojica MF; Rutter JD; Taracila M; Abriata LA; Fouts DE; Papp-Wallace KM; Walsh TJ; LiPuma JJ; Vila AJ; Bonomo RA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266860
[No Abstract] [Full Text] [Related]
26. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
27. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
28. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.
Sreenivasan P; Sharma B; Kaur S; Rana S; Biswal M; Ray P; Angrup A
J Antibiot (Tokyo); 2022 Aug; 75(8):454-462. PubMed ID: 35715617
[TBL] [Abstract][Full Text] [Related]
29. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
30. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)
Kang Y; Xie L; Yang J; Cui J
Front Cell Infect Microbiol; 2023; 13():1023948. PubMed ID: 37457958
[TBL] [Abstract][Full Text] [Related]
31. Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.
Bhatnagar A; Ransom EM; Machado MJ; Boyd S; Reese N; Anderson K; Lonsway D; Elkins CA; Rasheed JK; Patel JB; Karlsson M; Brown AC; Lutgring JD
J Antimicrob Chemother; 2021 Mar; 76(4):979-983. PubMed ID: 33367916
[TBL] [Abstract][Full Text] [Related]
32. Synergistic
Ract P; Compain F; Robin F; Decre D; Gallah S; Podglajen I
J Med Microbiol; 2019 Sep; 68(9):1292-1298. PubMed ID: 31361213
[No Abstract] [Full Text] [Related]
33. Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Lodise TP; O'Donnell JN; Balevic S; Liu X; Gu K; George J; Raja S; Guptill JT; Zaharoff S; Schwager N; Fowler VG; Wall A; Wiegand K; Chambers HF;
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0093622. PubMed ID: 36394326
[TBL] [Abstract][Full Text] [Related]
34. Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates.
Calvopiña K; Hinchliffe P; Brem J; Heesom KJ; Johnson S; Cain R; Lohans CT; Fishwick CWG; Schofield CJ; Spencer J; Avison MB
Mol Microbiol; 2017 Nov; 106(3):492-504. PubMed ID: 28876489
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic synergy testing of ceftazidime-avibactam with aztreonam in a university hospital having high number of metallobetalactamase producing bacteria.
Sahu C; Pal S; Patel SS; Singh S; Gurjar M; Ghoshal U
Infect Dis (Lond); 2020 Nov; 52(11):801-807. PubMed ID: 32628575
[TBL] [Abstract][Full Text] [Related]
36. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
37. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
